Acute coronary syndrome (ACS), including ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina (UA), is a major life-threatening manifestation of coronary artery disease.[@b1-asm-4-372]--[@b3-asm-4-372] Moreover, data from early in the thrombolytic era indicate that STEMI complicated by ventricular arrhythmia (VA) is associated with a greater risk of short- and long-term mortality.[@b4-asm-4-372]--[@b6-asm-4-372] This increased mortality rate has been shown with VA following NSTEMI as well.[@b7-asm-4-372] Data from the Global Registry of Acute Coronary Events (GRACE) Registry also showed a higher hospital mortality rate when VA complicated ACS and allowed identification of variables associated with the occurrence of VA.[@b8-asm-4-372] The incidence and prognosis of VA in ACS are not yet reported from Saudi Arabia. Accordingly, data in the Saudi Project for Assessment of Coronary Events (SPACE) registry were accessed to describe the incidence of clinical outcomes associated with VA in patients hospitalized with ACS in Saudi Arabia. Patient characteristics associated with an increased risk for developing VA were examined to establish a baseline from which further studies can determine temporal changes in the magnitude and prognosis associated with VA-related ACS.

PATIENTS AND METHODS
====================

This was a sub-study of the multicenter, prospective SPACE registry of ACS patients admitted to 17 government hospitals in Saudi Arabia between December 2005 and December 2007.[@b9-asm-4-372] Patients were categorized as having VA if they experienced either ventricular fibrillation (VF) or sustained ventricular tachycardia (VT) or both. VF was identified at admission or during the process of hospitalization if the patient showed irregular undulations of the electrocardiogram consistent with the diagnosis.[@b8-asm-4-372] VT was identified by a regular wide complex tachycardia lasting \>30 seconds or requiring termination because of hemodynamic instability.[@b8-asm-4-372] VA could be identified on presentation or during the index hospitalization.

An assigned physician in each hospital acquired patient data that were entered by trained study coordinators onto standardized electronic case report forms (CRFs) throughout the hospital stay for each patient. Data included the following variables for which definitions were standardized among participating hospitals: patient demographics, medical history, presenting symptoms, provisional diagnosis on admission and final discharge diagnosis, biochemical and electrocardiographic findings, laboratory investigations, medical therapy, use of cardiac procedures and interventions, in-hospital outcomes, and in-hospital mortality. All cases were categorized as STEMI, NSTEMI, or UA using the definition proposed by the Joint Committee of the European Society of Cardiology/American College of Cardiology.[@b3-asm-4-372] Cardiologists verified the completed CRFs and submitted them to the principal coordinating center where they were further checked for data quality, and queries were resolved before final analysis. All participating centers obtained ethics approval.

Differences in categorical variables between respective comparison groups were analyzed using the chi-square test or Fisher exact test. Continuous variables were analyzed using a *t* test or Mann-Whitney *U* test based on the satisfaction of normality assumption. *P* values are reported as 2-sided test results with a 5% level of significance for each test. Multiple logistic regression analysis was used to identify factors associated with VA. Variables considered for inclusion were baseline demographic characteristics (age, gender), medical history diabetes mellitus, hypertension, hyperlipidemia, coronary artery disease, angina, myocardial infarction \[MI\], cerebrovascular accident, percutaneous coronary intervention \[PCI\], coronary artery bypass graft), personal history (smoking), clinical presentation (Killip class \>I, heart rate \[HR\], systolic blood pressure, ejection fraction), and discharge diagnosis (STEMI, NSTEMI, UA). Further, logistic regression models were used to assess the possible effect of VA on in-hospital outcome, and multivariate logistic regression models were used to adjust for age, gender, and comorbidities to see if the mortality effect of VA was confounded by these variables. Logistic regression models were also used to assess the effect of VA on other in-hospital adverse events such as recurrent ischemia, re-myocardial infarction, cardiogenic shock, congestive heart failure (CHF), major bleeding, and stroke. All analyses were performed using STATA version 9 (StataCorp LP, United States).

RESULTS
=======

Of 5055 patients with ACS enrolled in the SPACE registry from December 2005 through December 2007, 168 (3.3%) developed VA during hospitalization of which 17 (1.2%) occurred at time of presentation to the hospital. The incidence of VA was significantly greater in patients with STEMI than in patients with NSTEMI/UA (6% vs 1.5%; *P*\<.001). The mean age of all ACS subjects was 58 (12.9) years, and was similar in patients with and without VA (*P*=.72) ([Table 1](#t1-asm-4-372){ref-type="table"}). A larger proportion of patients with VA were men compared with patients without VA (85.7% vs 77.2%; *P*=.004), and had a history of smoking (44.6% vs 32.0%; *P*\<.001). Fewer patients with in-hospital VA had a history of hyperlipidemia (24.4% vs 42.0%; *P*\<.001) and a history of coronary artery disease (33.9% vs 42.7%; *P*=.01). Other medical and personal history variables were similar between groups. On admission, patients with VA were significantly more likely than patients without VA to have Killip class \>I (36.4% vs 20.1%; *P*\<.001), systolic BP \<90 mm Hg (15.5% vs 2.8%; *P*\<.001), HR \>100 bpm (22.1% vs 14.6%; *P*=.010), and left ventricular ejection fraction \<35% (61.9% vs 33.6%; *P*\<.001). A greater proportion of VA patients compared with non-VA patients had STEMI (74.4% vs 40.3%), and a smaller proportion had NSTEMI (19.6% vs 37.0%) and UA (6.0% vs 22.7%; *P*\<0.001 for all comparisons). Patients with VA were hospitalized for a median of 8 days, compared with 5 days for those without VA (*P*\<.001).

Patients with VA were less likely than those without VA to receive the evidence-based therapies beta-blockers (62.3% vs 82.3%; *P*\<.001), angiotensin-converting enzyme inhibitors (ACEI, 58.7% vs. 69.9%; *P*=.002), IV anticoagulant (77.4% vs 82.8%; *P*=.046), and statins (87.4% vs 93.5%; *P*=.003); while they were more likely to have elevated troponin (66.1% vs 62.4%; *P*\<.001) ([Table 2](#t2-asm-4-372){ref-type="table"}). No differences were observed in the rate of interventions between the two groups.

On multivariate regression analysis, male gender, systolic blood pressure \<90 mm Hg, Killip class, and positive cardiac markers were independently associated with an increased risk for AV, while therapy with a history of hyperlipidemia was associated with a decreased risk of VA ([Table 3](#t3-asm-4-372){ref-type="table"}). In-hospital events and outcomes were more frequent in the presence of VA ([Table 4](#t4-asm-4-372){ref-type="table"}). Mortality was significantly higher in VA patients (27.0%) compared with non-VA patients (2.2%; *P*=.001)([Table 4](#t4-asm-4-372){ref-type="table"}). The impact of VA on in-hospital mortality for the overall population and ACS subtype remained high; however, it was attenuated after adjusting for age, gender, and comorbidities ([Table 5](#t5-asm-4-372){ref-type="table"}).

DISCUSSION
==========

The occurrence of VA in patients with ACS is of substantial importance in the clinical decision-making process. Large multinational studies have been conducted in recent years to determine the magnitude and prognosis associated with VA in patients hospitalized with ACS.[@b10-asm-4-372] Our multicenter, prospective data expand this knowledge base to include the incidence, associated factors, and outcomes of patients with ACS complicated by the development of serious arrhythmias. In this study VA occurred in 6% of patients with STEMI and 1.5% in patients with NSTEMI/UA.

The incidence of VA during hospitalization for ACS in our study is similar to that reported in previous studies of patients with STEMI and NSTEMI enrolled in randomized clinical trials (RCT).[@b7-asm-4-372] Additionally, RCT patients were more likely to be men[@b11-asm-4-372]--[@b13-asm-4-372] and have a history of coronary heart disease[@b14-asm-4-372] and hyperlipidemia,[@b15-asm-4-372] and have Killip class \>I on admission. Our baseline findings revealed less coronary artery disease and hyperlipidemia compared with these published studies. Characteristics that were more frequent in our non-VA patients including a history of coronary disease (angina, MI), PCI, diabetes mellitus, and hypertension are similar to results from the GRACE Registry. Moreover, less frequent use of evidence-based therapies including ACEI, beta-blockers, statins, and IV anticoagulants in our patients with VA compared with those without VA is similar to results reported previously[@b8-asm-4-372],[@b16-asm-4-372],[@b17-asm-4-372] The fact that more severely ill patients have increased complications, including VA, and may not tolerate medications such as ACEI and beta-blockers, may confound this finding.

Factors associated with an increased risk of developing VA during hospitalization for ACS were as follows: male gender, smoking, Killips class \>I, higher HR, lower systolic blood pressure, and positive cardiac markers; while factors associated with a decreased risk were as follows: prior history of hyperlipidemia, MI, CAD, beta-blockers, ACEI, and statins. It is noteworthy that these associations varied among published studies, which may be attributed to differences in the population studied; for example, some share our observation of increased risk with Killip \>I, positive cardiac marker, smoking, and high HR and decreased risk with prior MI.[@b8-asm-4-372] Few studies, however, found prior PCI associated with decreased risk. Similarly, prior PCI in our study predicted a decreased risk for VA. In contrast, Mehta et al reported from the APEX AMI trial that VA is associated with a more than 3-fold greater risk of 90-day mortality in patients undergoing primary PCI.[@b18-asm-4-372] The development of VA adversely influences the prognosis of patients with ACS. In our study, adverse events during hospitalization were more frequent in the VA group than in patients without VA. Interestingly, not only adverse events related to ischemia (recurrent ischemia and recurrent MI) and left ventricular dysfunction (CHF and cardiogenic shock) were significantly associated with the presence of VA, but other clinically relevant events (stroke and major bleeding) were also significantly increased in patients with VA. Therefore, patients with ACS who develop VA are at risk for cardiovascular and bleeding-related complications.[@b8-asm-4-372]

In-hospital mortality rates were extremely high in patients with VA. Some of this association was related to older age, male gender, and a higher prevalence of comorbid conditions, as shown by attenuation of the risk after adjustment for these factors in multivariate regression. In examining the impact of VA in patients with STEMI, several investigators documented high mortality rates during hospitalization, which was our observation as well. Our results are similar to those of other studies, including descriptive studies, RCTs, and registry studies, which document a higher risk of death in patients who develop VA.[@b6-asm-4-372],[@b7-asm-4-372],[@b18-asm-4-372] Therefore, timely identification of patients who are likely to develop a VA and proper management are crucial to improve prognosis for these patients.

A limitation of our study is that it was based on registry data which is a subject to missing data and selection biases inherent in the design of a registry. Moreover, the time of VA in relation to the revascularization and/or success of reperfusion therapy was not documented. This precludes ascertaining if patients with VA had not been reperfused or the VA developed before reperfusion therapy commenced. Therefore, our findings must be confirmed in future studies. Moreover, VA in our study included patients with VT and VF, which might have different prognostic implications in the setting of ACS; information with respect to the type of VA was not documented in our study. Finally, the pre-hospital VA and/or sudden death were not captured in this registry, which might underestimated the incidence of VA in our population.

In conclusion, information on the most powerful associated factors, such as an increased risk of VA occurring during hospitalization, is readily available in the patient's medical history, clinical presentation parameters, and laboratory findings at the time of hospital admission. This information can be used to identify patients at a greater risk for developing VA during hospitalization for ACS. As a complication of ACS, VA results in a poorer prognosis. Evaluating the simple risk factors identified in this study will aid in the decision-making process for daily clinical practice.

The SPACE registry is managed under the auspices of the Saudi Heart Association and financially sponsored by Sanofi-Aventis, which had no role in data extraction or analyses, the writing of the manuscript, or the decision to submit the manuscript for publication.

###### 

Baseline characteristics.

  ------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                                   Total\        Ventricular arrhythmia\                          No ventricular arrhythmia\   *P*
                                                    N (%)         n (%)[a](#tfn1-asm-4-372){ref-type="table-fn"}   n (%)                        
  ------------------------------------------------- ------------- ------------------------------------------------ ---------------------------- --------
  Total                                             5055          168 (3.3)                                        4887 (96.7)                  

  Mean age, years (SD)                              58 (12.9)     57.7 (14.9)                                      58 (12.9)                    .72

  Men                                               3914 (77.4)   144 (85.7)                                       3770 (77.2)                  .004

  Diabetes mellitus                                 2935 (58.2)   93 (55.4)                                        2842 (58.3)                  .25

  Hypertension                                      2782 (55.0)   83 (49.4)                                        2699(55.2)                   .18

  Hyperlipidemia                                    2084 (41.4)   41 (24.4)                                        2043 (42.0)                  \<.001

  Coronary artery disease                           2145 (42.4)   57 (33.9)                                        2088 (42.7)                  .014

  Angina                                            1399 (40.2)   38 (31.7)                                        1361 (40.4)                  .155

  Myocardial infarction                             915 (26.3)    21 (17.5)                                        894 (26.6)                   .079

  Cerebrovascular accident                          309 (6.1)     14 (8.3)                                         295 (6.0)                    .56

  Percutaneous coronary intervention                698 (13.8)    17 (10.1)                                        681 (13.9)                   .084

  Coronary artery bypass graft                      296 (5.9)     11 (6.5)                                         285 (5.8)                    .87

  Smoking                                           1637 (32.4)   75 (44.6)                                        1562 (32.0)                  \<.001

  Clinical presentation                                                                                                                         

  Killip class \>I                                  937 (20.6)    55 (36.4)                                        882 (20.0)                   \<.001

  Heart rate \>100                                  679 (14.9)    33 (22.1)                                        646 (14.6)                   .010

  Systolic blood pressure \<90                      148 (3.2)     23 (15.5)                                        125 (2.8)                    \<.001

  Ejection fraction \<35%                           1149 (34.5)   70 (61.9)                                        1079 (33.6)                  \<.001

  **Diagnosis**                                                                                                                                 

   ST-segment elevation myocardial infarction       2096 (41.5)   125 (74.4)                                       1971 (40.3)                  \<.001

   Non-ST-segment elevation myocardial infarction   1840 (36.4)   33 (19.6)                                        1807 (37.0)                  \<.001

   Unstable angina pectoris                         1119 (22.1)   10 (6.0)                                         1109 (22.7)                  \<.001

   Median length of hospitalization, days           5             8                                                5                            \<.001
  ------------------------------------------------------------------------------------------------------------------------------------------------------

Number and % of column total unless otherwise indicated.

###### 

In-hospital management.

  Variables, n (%)                           Total (N=5055)   Ventricular arrhythmia (n=168)   No ventricular arrhythmia (n=4887)   *P*
  ------------------------------------------ ---------------- -------------------------------- ------------------------------------ --------
  **Treatment**                                                                                                                     
   Aspirin                                   4929 (97.8)      160 (95.8)                       4769 (97.8)                          .08
   Clopidogrel                               4227 (83.9)      134 (80.2)                       4093 (84.0)                          .121
   Beta-blocker                              4115 (81.6)      104 (62.3)                       4011 (82.3)                          \<.001
   Angiotensin converting enzyme inhibitor   3504 (69.5)      98 (58.7)                        3406(69.9)                           .002
   Angiotensin receptor blocker              297 (5.9)        6 (3.6)                          291 (6.0)                            .13
   Statin                                    4705 (93.3)      146 (87.4)                       4559 (93.5)                          .003
   Anticoagulant                             4176(82.6)       130 (77.4)                       4046 (82.8)                          .046
   IV insulin \<24 h                         479 (13.8)       27 (22.7)                        452 (13.5)                           .005
   Troponin                                  3149 (62.5)      111 (66.1)                       3038 (62.4)                          \<.001
                                                                                                                                    
  **Intervention**                                                                                                                  
   Coronary angiogram                        3397 (67.2)      100 (59.5)                       3297 (67.5)                          .05
   Percutaneous coronary intervention        1776 (35.3)      62 (36.9)                        1714 (35.2)                          .49
   Coronary artery bypass graft              425 (8.5)        17 (10.2)                        408 (8.4)                            .79

Values are number and percentage.

###### 

Multivariate regression analysis of factors associated with in-hospital ventricular arrhythmia in acute coronary syndrome patients.

  All ACS patients                     Odds ratio   95% CI      P
  ------------------------------------ ------------ ----------- --------
  Gender (male)                        1.7          1.1--3.1    .040
  Systolic blood pressure \<90 mm Hg   6.3          3.4--11.5   \<.001
  Killip class \>1                     2.3          1.5--3.6    \<.001
  Positive cardiac markers             2.3          1.2--4.7    .018
  Hyperlipidemia                       0.49         0.3--0.7    \<.001

###### 

In-hospital outcomes in patients with acute coronary syndrome with and without ventricular arrhythmia (VA).

  Hospital event             Total (N=5055)   VA (n=168)   No VA (n=4887)   *P*
  -------------------------- ---------------- ------------ ---------------- --------
  Death                      155 (3.1)        46 (27.0)    109 (2.2)        \<.001
  Recurrent ischemia         638 (12.6)       56 (33.3)    582 (11.9)       \<.001
  Re-myocardial infarction   77 (1.5)         10 (6.0)     67 (1.4)         \<.001
  Cardiogenic shock          222 (4.4)        65 (38.9)    157 (3.2)        \<.001
  Congestive heart failure   520 (10.3)       66 (39.3)    454 (9.3)        \<.001
  Major bleeding             68 (1.3)         10 (6.0)     58 (1.2)         \<.001
  Stroke                     48 (1.0)         6 (3.6)      42 (0.9)         .004

Values are number and percentage.

###### 

Impact of ventricular arrythmia on in-hospital death in acute coronary syndrome (ACS) patients.

                                                                                   Odds ratio (95% CI)   *P*
  -------------------------------------------------------------------------------- --------------------- --------
  All ACS                                                                          16.5 (11.2--24.9)     \<.001
  Age adjusted                                                                     18.6 (12.3--27.9)     \<.001
  Age and gender adjusted                                                          20 (13.5--31.5)       \<.001
  Age, gender, and comorbidiesa adjusted                                           13.1 (7.2--24.1)      \<.001
  ST-segment elevation myocardial infarction                                       11.1 (6.9--17.7)      \<.001
  Age adjusted                                                                     13.1 (7.9--21.6)      \<.001
  Age and gender adjusted                                                          13.7 (8.1--22.9)      \<.001
  Age, gender, and comorbidies[a](#tfn4-asm-4-372){ref-type="table-fn"} adjusted   11.1 (5.2--23.5)      \<.001
  Non-ST segment elevation myocardial infarction/Unstable angina pectoris          26.5 (12.9--53.9)     \<.001
  Age adjusted                                                                     22.5 (10.8--47.1)     \<.001
  Age and gender adjusted                                                          26.3 (12.3--56.2)     \<.001
  Age, gender, and comorbidies[a](#tfn4-asm-4-372){ref-type="table-fn"} adjusted   14.1 (4.3--45.7)      \<.001

History of prior MI, PCI, angina, CABG, CVA, smoking, HTN, DM, and hyperlipidemia.
